Literature DB >> 10411991

Selective oxidation and externalization of membrane phosphatidylserine: Bcl-2-induced potentiation of the final common pathway for apoptosis.

N F Schor1, Y Y Tyurina, J P Fabisiak, V A Tyurin, J S Lazo, V E Kagan.   

Abstract

The induction of apoptosis in PC12 cells by the enediyne neocarzinostatin (NCS) is paradoxically potentiated by overexpression of bcl-2. The enhanced activation of NCS seen in bcl-2-overexpressing cells cannot by itself be responsible for the potentiation of apoptosis, since Bcl-2 would be expected to block apoptosis at a point distal to NCS activation (e.g., in the apoptosis final common pathway). We now report that overexpression of bcl-2 in PC12 cells does not protect the cells from NCS-induced oxidation of membrane phosphatidylserine (PS), and results in potentiation of NCS-induced externalization of membrane PS, two events associated with the apoptosis final common pathway. The mechanism of potentiation of apoptosis by Bcl-2 is related to the enhanced reducing potential of bcl-2-overexpressing PC12 cells. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411991     DOI: 10.1016/s0006-8993(99)01414-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Depletion of Bcl-2 by an antisense oligonucleotide induces apoptosis accompanied by oxidation and externalization of phosphatidylserine in NCI-H226 lung carcinoma cells.

Authors:  Patrick P Koty; Yulia Y Tyurina; Vladimir A Tyurin; Shang-Xi Li; Valerian E Kagan
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

Review 2.  The role of the macrophage in apoptosis: hunter, gatherer, and regulator.

Authors:  F Jon Geske; Jenifer Monks; Lisa Lehman; Valerie A Fadok
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

3.  Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy.

Authors:  Danny Rogers; Karen D Nylander; Zhiping Mi; Tong Hu; Nina F Schor
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-13       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.